Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


European Commission approves Doptelet for treatment of severe thrombocytopenia – Dova Pharma

Written by | 10 Jul 2019

Dova Pharmaceuticals, Inc announced that the European Commission (EC) has granted marketing authorization for Doptelet (avatrombopag) for the treatment of severe thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled to undergo an invasive procedure.

EMA validates MAA for Exparel for post surgical analgesia – Pacira Pharma

Written by | 10 Jul 2019

Pacira BioSciences, Inc. announced that the company’s Marketing Authorization Application (MAA) for Exparel (bupivacaine liposome injectable suspension) for postsurgical analgesia was validated by the European Medicines Agency (EMA).

State of the art clinical trials

Written by | 6 May 2019

Professor Sagar Lonial (Atlanta, USA) opened the UKMF by discussing the latest evidence in the management of myeloma, with comment from session chair Professor Gordon Cook (Leeds, UK).

Frontline therapy in multiple myeloma therapy: current evidence and future research

Written by | 2 May 2019

Professor Graham Jackson (Newcastle, UK) held a ‘meet the expert’ session at BSH 2019 covering the rapidly changing world of frontline therapy in myeloma.

Translational science in IBD

Written by | 9 Apr 2019

Dr Bram Verstockt (Leuven, Belgium) discusses a biopsy study looking at increases NCR+ ILC3 levels in IBD patients on biologic therapy.

DDW 2018: Predicting who will get IBD

Written by | 2 Oct 2018

To have a chance of preventing IBD clinicians need to be able to predict who is at risk, based on sensitive and selective risk factors. In a translational… read more.

DDW 2018: Choice in patient management

Written by | 2 Oct 2018

IBD specialists have more treatment options than ever before; yet the optimal use of many agents, old as well as new, remains to be defined. A plenary session… read more.

EHA 2018: Immunotherapy in MM: why, when and how?

Written by | 24 Jun 2018

The pathophysiology of MM is characterised by a state of profound immunosuppression through multiple mechanisms which provides a strong rationale for immunotherapeutic approaches including antibodies, immunomodulators, vaccines and… read more.

EHA 2018: Preferred treatment combinations and sequencing in transplant eligible and elderly MM patients

Written by | 24 Jun 2018

The growing number of novel treatments for multiple myeloma (MM) means that more patients can achieve the therapeutic goal of a deep and prolonged first remission – in… read more.

BSH 2018: Hodgkin lymphoma: tackling treatment challenges in the older patient

Written by | 21 Jun 2018

Managing Hodgkin lymphoma in elderly patients can be challenging, given that trial data do not reflect the picture in elderly patients and performance status can vary widely. The… read more.

BSH 2018: Access to new agents

Written by | 11 May 2018

Cancer drugs receive special funding in the NHS but it is not automatic and input from expert clinicians is essential to ensure that effective treatments are funded appropriately…. read more.

Length of lactation inversely related to diabetes development

Written by | 25 Apr 2018

Lactation duration appears to be inversely related to development of type 2 diabetes, researchers reported in the March 2018 issue of JAMA Internal Medicine.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.